(NASDAQ: EVGN) Evogene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 21.94%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 68.29%.
Evogene's earnings in 2026 is -$8,485,000.On average, 3 Wall Street analysts forecast EVGN's earnings for 2026 to be -$13,338,835, with the lowest EVGN earnings forecast at -$12,815,744, and the highest EVGN earnings forecast at -$13,731,154. On average, 3 Wall Street analysts forecast EVGN's earnings for 2027 to be -$7,114,045, with the lowest EVGN earnings forecast at -$6,835,063, and the highest EVGN earnings forecast at -$7,323,282.
In 2028, EVGN is forecast to generate -$4,890,906 in earnings, with the lowest earnings forecast at -$4,699,106 and the highest earnings forecast at -$5,034,756.